CY1122837T1 - Θεραπεια της γυροειδους αλωπεκιας - Google Patents

Θεραπεια της γυροειδους αλωπεκιας

Info

Publication number
CY1122837T1
CY1122837T1 CY20201100268T CY201100268T CY1122837T1 CY 1122837 T1 CY1122837 T1 CY 1122837T1 CY 20201100268 T CY20201100268 T CY 20201100268T CY 201100268 T CY201100268 T CY 201100268T CY 1122837 T1 CY1122837 T1 CY 1122837T1
Authority
CY
Cyprus
Prior art keywords
alopecia areata
treatment
diazaspiro
octan
pyrrolo
Prior art date
Application number
CY20201100268T
Other languages
Greek (el)
English (en)
Inventor
Michael Sierra
Tord LABURA
Atsuo Tanimoto
Yuichi Shinozaki
Original Assignee
Leo Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2015190849A external-priority patent/JP2017066061A/ja
Application filed by Leo Pharma A/S filed Critical Leo Pharma A/S
Publication of CY1122837T1 publication Critical patent/CY1122837T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CY20201100268T 2015-09-24 2020-03-20 Θεραπεια της γυροειδους αλωπεκιας CY1122837T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15186644 2015-09-24
JP2015190849A JP2017066061A (ja) 2015-09-29 2015-09-29 円形脱毛症治療剤
PCT/EP2016/072531 WO2017050891A1 (en) 2015-09-24 2016-09-22 Treatment of alopecia areata

Publications (1)

Publication Number Publication Date
CY1122837T1 true CY1122837T1 (el) 2021-05-05

Family

ID=57047187

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100268T CY1122837T1 (el) 2015-09-24 2020-03-20 Θεραπεια της γυροειδους αλωπεκιας

Country Status (27)

Country Link
US (3) US20180263986A1 (enExample)
EP (1) EP3352734B1 (enExample)
JP (1) JP6776345B2 (enExample)
KR (1) KR102728341B1 (enExample)
CN (1) CN108135834B (enExample)
AU (3) AU2016325388A1 (enExample)
BR (1) BR112018005771B1 (enExample)
CA (1) CA2998972A1 (enExample)
CY (1) CY1122837T1 (enExample)
DK (1) DK3352734T3 (enExample)
ES (1) ES2779762T3 (enExample)
HR (1) HRP20200472T1 (enExample)
HU (1) HUE049052T2 (enExample)
IL (3) IL312861A (enExample)
LT (1) LT3352734T (enExample)
MX (1) MX375024B (enExample)
MY (1) MY196541A (enExample)
PL (1) PL3352734T3 (enExample)
PT (1) PT3352734T (enExample)
RS (1) RS60365B1 (enExample)
RU (1) RU2754997C2 (enExample)
SG (1) SG10202111361TA (enExample)
SI (1) SI3352734T1 (enExample)
TW (1) TWI720022B (enExample)
UA (1) UA124192C2 (enExample)
WO (1) WO2017050891A1 (enExample)
ZA (1) ZA201801722B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119367282A (zh) * 2019-12-27 2025-01-28 乐敦制药株式会社 水性组合物
WO2023029943A1 (zh) * 2021-09-03 2023-03-09 星药科技(北京)有限公司 一种芳杂环化合物及其制备方法和用途
JP2025514747A (ja) 2022-04-20 2025-05-09 レオ ファーマ アクティーゼルスカブ 前頭部線維性脱毛症の治療

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US8637569B2 (en) * 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2015060208A1 (ja) * 2013-10-21 2015-04-30 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤

Also Published As

Publication number Publication date
JP2018528238A (ja) 2018-09-27
SG10202111361TA (en) 2021-12-30
UA124192C2 (uk) 2021-08-04
LT3352734T (lt) 2020-04-10
RS60365B1 (sr) 2020-07-31
DK3352734T3 (da) 2020-03-30
ZA201801722B (en) 2025-06-25
AU2016325388A1 (en) 2018-03-29
EP3352734B1 (en) 2020-01-15
NZ740690A (en) 2024-11-29
ES2779762T3 (es) 2020-08-19
RU2754997C2 (ru) 2021-09-08
EP3352734A1 (en) 2018-08-01
IL298520A (en) 2023-01-01
SI3352734T1 (sl) 2020-07-31
BR112018005771B1 (pt) 2023-12-05
HUE049052T2 (hu) 2020-09-28
MY196541A (en) 2023-04-19
CA2998972A1 (en) 2017-03-30
CN108135834A (zh) 2018-06-08
US20180263986A1 (en) 2018-09-20
KR20180054767A (ko) 2018-05-24
IL312861A (en) 2024-07-01
AU2024204716B2 (en) 2026-06-11
AU2022202508A1 (en) 2022-05-12
HRP20200472T1 (hr) 2020-09-18
JP6776345B2 (ja) 2020-10-28
US20240398809A1 (en) 2024-12-05
RU2018114922A (ru) 2019-10-28
MX2018003332A (es) 2018-08-16
PL3352734T3 (pl) 2020-08-24
TWI720022B (zh) 2021-03-01
CN108135834B (zh) 2021-07-27
WO2017050891A1 (en) 2017-03-30
PT3352734T (pt) 2020-03-31
RU2018114922A3 (enExample) 2019-12-11
US20220088020A1 (en) 2022-03-24
BR112018005771A2 (pt) 2018-10-09
AU2024204716A1 (en) 2024-07-25
KR102728341B1 (ko) 2024-11-11
MX375024B (es) 2025-03-06
HK1257770A1 (en) 2019-10-25
TW201717955A (zh) 2017-06-01
IL257918A (en) 2018-05-31

Similar Documents

Publication Publication Date Title
NI201800128A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
NZ721617A (en) Heterocyclic compounds
CY1126388T1 (el) Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων
MX372997B (es) Compuestos de aminopirimidina como inhibidores de jak.
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
CU20170162A7 (es) Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen
CL2016001895A1 (es) Compuestos
EA201692003A1 (ru) Макроциклические производные пиримидина
ECSP18024565A (es) Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
EA201692000A1 (ru) Макроциклические производные пиридина
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
MX374555B (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
UY35625A (es) Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
MX2018004664A (es) Antagonistas de ep4.
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
CY1117881T1 (el) Στερεες φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα βιοπτερινης και χρησεις αυτων των συνθεσεων
MX2018004868A (es) Derivados de la pirrolidina.
ZA201801722B (en) Treatment of alopecia areata
CY1123185T1 (el) Παραγωγα ινδολιου
EA201990046A1 (ru) Производные бициклического пиридина, пиразина и пиримидина в качестве ингибиторов pi3k бета
TR201910896T4 (tr) Özgün 6,7-dihidro-3H-oksazolo[3,4-A]pirazin-5,8-dion türevi bileşikler.